Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Inclusion Criteria

• •Males or females aged \>/= 18 years
• •Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucinous or clear cell tumors) or Adenocarcinoma of the prostate
• •At least 1 unidimensional measurable lesion (suitable for RECIST evaluation) or for patients without measurable disease, CA 125 levels \>/= 2 times the upper limit of normal (ULN) within 3 months and confirmed within 2 weeks prior to first infusion (ovarian cancer) or PSA value \>/= 5 ng/mL (HRPC).
• •Progression of disease (HRPC) despite adequate androgen-inhibiting hormone therapy.
• •Progression of disease (Ovarian Cancer) or symptomatic relapse after previous therapy (elevated CA125 levels alone are insufficient for inclusion) WHO performance status 0 to 1
• •No clinical residual neuropathy (CTCAE Grade 0 at baseline)
• •Adequate recovery from previous surgery, radiation, and chemotherapy (excluding alopecia)
• •Adequate function of major organs and systems.
• •Survival expectation =3 months
• •Histologically or cytologically proven:
• •1. Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucionous cell tumors or clear cell tumors that have a clear cell component of \>33%)